Iodine status of young Burkinabe children receiving small-quantity lipid-based nutrient supplements and iodised salt : a cluster-randomised trial by Hess, Sonja Y et al.
Iodine status of young Burkinabe children receiving small-quantity lipid-based
nutrient supplements and iodised salt: a cluster-randomised trial
Sonja Y. Hess1*, Souheila Abbeddou1, Elizabeth Yakes Jimenez2, Jean-Bosco Ouédraogo3 and
Kenneth H. Brown1,4
1Program in International and Community Nutrition, Department of Nutrition, University of California Davis, Davis,
CA 95616, USA
2Nutrition Program, Department of Individual, Family and Community Education, University of New Mexico, Albuquerque,
NM 87131, USA
3Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso 01, Burkina Faso
4Bill & Melinda Gates Foundation, Seattle, WA 98109, USA
(Submitted 13 May 2015 – Final revision received 10 August 2015 – Accepted 12 August 2015 – First published online 28 September 2015)
Abstract
The objective of the present study was to assess the impact of providing small-quantity lipid-based nutrient supplements (SQ-LNS) on the
I status of young Burkinabe children. In total, thirty-four communities were assigned to intervention (IC) or non-intervention cohorts (NIC). IC
children were randomly assigned to receive 20 g lipid-based nutrient supplements (LNS)/d containing 90 µg I with 0 or 10mg Zn from 9 to
18 months of age, and NIC children received no SQ-LNS. All the children were exposed to iodised salt through the national salt iodization
programme. Spot urinary iodine (UI), thyroid-stimulating hormone (TSH) and total thyroxine (T4) in dried blood spots as well as plasma
thyroglobulin (Tg) concentrations were assessed at 9 and 18 months of age among 123 IC and ﬁfty-six NIC children. At baseline and at
18 months, UI, TSH and T4 did not differ between cohorts. Tg concentration was higher in the NIC v. IC at baseline, but this difference did not
persist at 18 months of age. In both cohorts combined, the geometric mean of UI was 339·2 (95 % CI 298·6, 385·2) µg/l, TSH 0·8 (95 % CI 0·7,
0·8) mU/l, T4 118 (95 % CI 114, 122) nmol/l and Tg 26·0 (95 % CI 24·3, 27·7) µg/l at 18 months of age. None of the children had elevated TSH at
18 months of age. Marginally more children in NIC (8·9 %) had low T4 (<65 nmol/l) compared with the IC (1·6 %) (P= 0·052). Salt samples
(n 106) were collected from randomly selected participants and assessed by titration for I content, which was on average 37 (SD 15) ppm
(range 5–86 ppm); 95 % of households had adequately iodised salt (I> 15 ppm). A reduction of SQ-LNS I content could be considered in
settings with similarly successful salt iodisation programmes.
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Thyroid hormones
I is essential for the human body because it is required for
thyroid hormone production. Owing to its importance in
thyroid metabolism, adequate I is particularly critical for normal
foetal and young child growth and development. Inadequate
intake of I results in a spectrum of disorders, including goitre,
impaired cognitive development and congenital abnormalities,
generally referred to as I-deﬁciency disorders(1).
The I content of food depends on the local soil content and
animal feeding practices. Thus, I deﬁciency generally occurs in
regions with low soil I content(2). In areas at risk of I deﬁciency,
salt iodisation remains the key strategy to prevent and control
I deﬁciency(3). In the early 1990s, I deﬁciency was very
common, and the UNICEF estimated that <20 % of households
in low-income countries were using iodised salt, which
increased to 70 % by 2000(4). In countries at risk of I deﬁciency,
where universal salt iodisation programmes do not achieve high
coverage, other I supplementation strategies are recommended.
In particular, the WHO and UNICEF recommend providing
I supplements to pregnant and lactating women and I-fortiﬁed
complementary foods to children aged 7–24 months when
iodised salt coverage is <50 %(5). In countries with coverage of
50–90 %, efforts should be made to improve universal salt
iodisation, and targeted provision of supplementary I should be
considered in the meantime.
The WHO, the International Council for the Control of Iodine
Deﬁciency Disorders and UNICEF recommend an intake of
90 µg I/d for children< 60 months of age(3), whereas the US
Institute of Medicine recommends 110–130 µg/d for children
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aged between 0 and 12 months and 90 µg/d for children
between 1 and 8 years of age(6). Home fortiﬁcation products
such as micronutrient powders (MNP) and small-quantity lipid-
based nutrient supplements (SQ-LNS) are alternative vehicles
for providing micronutrients including I to young children.
Although the current MNP recommendations by WHO do not
specify the amount of I in MNP(7), the Home Fortiﬁcation
Technical Advisory Group recommends including 90 µg/d(8).
For the present study, SQ-LNS for young children was designed
to provide 90 µg I/20 g (493 kJ (118 kcal)) daily portion, along
with additional protein, essential fatty acids and other micro-
nutrients(9). Previous studies of MNP and SQ-LNS focused on
the assessment of young children’s anaemia and iron status,
and only a few studies investigated the impact on other
micronutrients such as vitamins A and B12 and Zn status
(10–13).
To date, there is no information available on the impact of
providing MNP or SQ-LNS on young children’s I status.
The primary objective of the present study was to assess the
impact of supplementing local complementary foods with
I-fortiﬁed SQ-LNS on the I status of young Burkinabe children
exposed to iodised salt. In Burkina Faso, the addition of I to salt
is mandatory since 2003. The regulations require an I content of
50–80 ppm at the time of importation and >30 ppm at retail
distribution sites(14). At the time when the present study was
planned, available data from the 2003 National Demographic
and Health Survey (DHS) indicated that only 34 % of house-
holds consumed iodised salt with >15 ppm I(15).
There are suggestions that Zn is important for normal thyroid
homoeostasis(16). A secondary objective of the present study
was to assess the impact of Zn intake on I status by comparing
groups that received SQ-LNS containing either 10 mg Zn/d or
no added Zn in a population considered to be at elevated risk
for Zn deﬁciency.
Methods
Participants
The present study was part of the larger iLiNS-ZINC trial, which
is described in more detail elsewhere(11). In brief, the study was
designed as a partially masked, placebo-controlled, cluster-
randomised intervention trial conducted from April 2010 to July
2012 in rural communities of the Dandé Health District in
southwestern Burkina Faso. This study was conducted accord-
ing to the guidelines laid down by the Declaration of Helsinki,
and all the procedures involving human subjects were
approved by the Institutional Review Boards of the Centre
Muraz in Bobo-Dioulasso (Burkina Faso) and the University of
California Davis (USA). All the participating guardians/care-
givers provided their written informed consent. The study was
registered as a clinical trial with the US National Institutes of
Health (www.ClinicalTrials.gov; NCT00944281).
Children were examined for eligibility based on the following
inclusion criteria: 8·8–9·9 months of age, permanent residence
in the area and planned availability during the study period.
Children were excluded based on the following criteria: Hb
levels <50 g/l, weight-for-length<70 % of the median of the
National Center for Health Statistics (NCHS)/WHO growth
reference(17), presence of bipedal oedema, other severe
illnesses warranting hospital referral, congenital abnormalities
potentially interfering with growth, chronic medical conditions
requiring frequent medical attention, known HIV infection
of infant or mother, history of allergy towards peanuts, history
of anaphylaxis or serious allergic reaction to any substance
requiring emergency medical care and concurrent participation
in any other clinical trial.
Sample size
The sample size estimates for the I status assessments were
based on the number of children required to detect an effect
size of 0·6 (with a signiﬁcance level of P< 0·05 and power
>0·80), which was considered to be of public health
signiﬁcance. The target sample size per intervention group for
biochemical indicators of I status was n 55, which was
increased to n 69 to include an assumed attrition rate of 20 %.
Owing to the cluster sampling design, the estimated sample size
for the non-intervention cohort (NIC) was increased to n 103
for an assumed design effect of 1·5 (including 20 % for attrition).
Salt samples were collected from a randomly selected
subsample of participants. The sample size estimates were
based on the number of household salt samples required for
each type of intervention to detect (with a signiﬁcance of
P< 0·05 and power> 0·80) effect sizes that are consistent with
the magnitude of differences observed in the salt analyses
conducted in northern Côte d’Ivoire(18). Assuming that
approximately 15–20 % of the caregivers would not provide a
salt sample, the target sample size per cohort (intervention
cohort (IC) v. NIC) was approximately 50.
Interventions
In total, thirty-four communities were stratiﬁed by a statistician
at the University of California Davis using selected indicators
(population size; proximity to road and Bobo-Dioulasso; and
health clinic afﬁliation) and assigned within strata to participate
in the IC (twenty-ﬁve communities) or NIC (nine communities).
Within the IC, children were randomly assigned to one of four
intervention groups, which received 20 g SQ-LNS daily
containing different amounts of Zn from 9 to 18 months of
age(11). For the present I impact study, only two intervention
groups and the NIC participated in the I assessment: (1) SQ-LNS
without Zn and placebo tablet (LNS-Zn0), (2) SQ-LNS with
10 mg Zn and placebo tablet (LNS-Zn10) and (3) NIC. For the
purpose of the primary objective of the previously reported trial
of the effects of different amounts of Zn in SQ-LNS v. dispersible
Zn tablets(11), all the children in the intervention groups
included in the present analyses also received a placebo tablet
daily. Children in the intervention groups received free
treatment for diarrhoea, malaria and fever, as described in
more detail elsewhere(11). Children in the NIC did not receive
SQ-LNS, tablets or any illness treatments during the study
period.
The SQ-LNS products were developed and produced for the
iLiNS project by Nutriset SAS and tested for acceptability before
the trial(9,19). The caregivers were advised to feed the daily
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ration of 20 g with two separate meals. The placebo tablets
were also produced by Nutriset SAS. Caregivers were advised to
continue breast-feeding and to provide children with a variety
of nutritious local foods.
Data collection
At enrolment, children’s age was conﬁrmed from the
health card, children’s length and weight were measured and
family socio-economic data were recorded, as previously
described(11). A capillary blood sample was collected for the
assessment of Hb concentration (Hemocue 201+; HemoCue® AB)
and to perform a rapid diagnostic test (RDT) for malaria
parasites (SD BIOLINE Malaria Ag P.F/Pan; Standard
Diagnostics Inc.). In case of anaemia (Hb< 80 g/l) and
uncomplicated illnesses at time of enrolment, all the children
received free treatment according to national policy(11). At 9 and
18 months of age, the children’s dietary practices were assessed
using non-quantitative food frequency questionnaires that
elicited information on food groups consumed in the previous
24 h and in the previous 7 d(20).
A subset of children (n 661) from LNS-Zn0, LNS-Zn10 and
NIC were randomly selected for the biochemistry subgroup and
were asked to provide venous blood and spot urine samples, as
described below (Fig. 1). The biochemistry subgroup included
a child if she or he was (1) the ﬁrst in the concession (i.e. family
compound) to be enroled in the study to avoid intra-cluster
bias, (2) did not participate in any other substudy(21,22) and
(3) was free from fever and diarrhoea symptoms for the
previous 48 h according to the caregiver. Children were
assigned to the biochemistry subgroup progressively until the
target sample size was reached. Household salt samples were
collected from randomly selected households in this subgroup.
In the IC 24 % (n 64 of 268) and in NIC 62 % (n 64 of 103) of all
biochemical participants were assigned to the salt subgroup.
Selected mothers were given a small plastic bag on the day of
enrolment and were asked to return with a salt sample from
their home on the day of blood and urine collection; 106 salt
samples were successfully collected. Venous blood was collected
in evacuated, trace element-free polyethylene tubes containing
lithium heparin (Sarstedt AG & Co.), stored on ice and trans-
ported to the ﬁeld laboratory, where dried blood spots (DBS)
were collected on ﬁlter paper and then stored with desiccant in
sealed bags. Plasma was separated from heparinised venous
blood by centrifuging at 2800 rpm for 10min. Plasma, DBS and
urine samples were stored at −20°C until shipped on dry ice to
the respective laboratories for analysis. Salt samples were stored
in a dry room with controlled temperature until analysis.
Laboratory analyses
I status was assessed based on urinary iodine (UI), whole-blood
thyroid-stimulating hormone (TSH) and total thyroxine (T4) and
plasma thyroglobulin (Tg) concentrations. Total I content of salt
samples was determined by iodometric titration at the Institut
de Recherche en Sciences de la Santé in Bobo-Dioulasso(23).
UI was assessed at the Medical Research Council in Cape Town,
South Africa, using a modiﬁcation of the Sandell–Kolthoff
reaction(24). DBS were analysed for TSH and total T4 con-
centrations by an automated time-resolved ﬂuoroimmunoassay
(DELFIA neonatal TSH and T4 assays; PerkinElmer Life
Sciences) at the Children’s Hospital in Zurich, Switzerland(25).
Participants screened for eligibility (n 3402)*
• No parental consent (n 55)
• Excluded due to unavailability (n 55)
• Excluded due to poor physical condition (n 26)
• Excluded one twin (n 46)
Participants enroled and randomly assigned (n 3220)
Intervention cohort
25 communities; 1799 concessions 
(n 2435)
LNS-Zn5
9-month visit
447 concessions
(n 613)†
I sub-study
(n 92)§
LNS-TabZn5 
9-month visit
449 concessions
(n 617)†
LNS-Zn0
9-month visit
455 concessions
(n 602)
203 selected at
9 months
139 invited‡
LNS-Zn10
9-month visit
448 concessions
(n 603)
199 selected at
9 months
129 invited
I sub-study
(n 88)
Non-intervention cohorts (NIC)
9 communities;
591 concessions  
NIC
9-month visit
591 concessions
(n 785)
259 selected at
9 months
163 invited
I sub-study
(n 104)
Fig. 1. Flow diagram of clusters and participant progression through the I impact assessment of the iLiNS-ZINC trial. * Eligiblity was determined at the level of the
child. † Not participating in the I impact assessment study. ‡ Invited if free of symptomatic fever or diarrhoea for 48 h before blood draw. § Number of children who
successfully provided blood and/or urine samples at both time points (9 and 18 months).
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Tg was assessed in plasma using the Immulite 1000 Immuno-
assay system (Siemens) at the University of California Davis.
Inadequate I status was deﬁned as UI< 100 µg/l(26). The
manufacturer’s normal reference range for TSH was
0·1–3·7mU/l and for T4 65–165 nmol/l. There is currently a
recommended normal range for Tg assessed in DBS available
for only school-age children (4–40 µg/l), but not for young
children(3). As there are no reference values available for young
children, we also explored differences between intervention
groups or cohorts at 18 months of age using standardised values
and based on the upper and lower 2·5th percentile of the adjusted
values for baseline values of the whole sample using general
linear models. This study will report on data collected from
the subgroup of children who successfully provided blood
and/or urine samples both at 9 and 18 months of age for the
analyses of I status.
Statistical analyses
Statistical analyses were carried out using SAS software for
Windows (9.3; SAS Institute) using mixed models to account for
the random effect of the community. Descriptive statistics
(mean values and standard deviations, geometric means and
95 % CI and proportions) were used to assess baseline
information by group and cohort, as well as to compare
children included in the I add-on study with those not included.
Length-for-age Z-score and weight-for-length Z-score were
calculated using the SAS macros for the WHO Child Growth
Standards(27). Breast-feeding and 24 h-complementary feeding
indicators were constructed according to WHO guidelines(20).
Any variables not normally distributed were transformed using
Box–Cox transformations to identify the optimal transformation
that leads to normality. Analyses were carried out using natural
logarithmically transformed TSH and UI and with square root
transformed Tg, which were back transformed for reporting
descriptive results.
I status indicators (UI, T4, TSH and Tg) were compared by
study group and cohort using mixed model ANCOVA for con-
tinuous outcome variables (SAS PROC MIXED procedure) and
mixed models logistic regression for dichotomous variables
(SAS PROC GLIMMIX procedure). Intervention group and
cohort were used as the main effects, and covariates were
tested individually in a binary model before including only the
variables with P< 0·1 in the ﬁnal model. Intervention group
means were compared post hoc using least-square means with
the Tukey–Kramer test.
Results
Of the 3220 children enroled in the iLiNS-ZINC trial (Fig. 1), 661
were randomly assigned to the biochemical substudy, and 431
of those children were free of reported fever and diarrhoea 48 h
before the blood collection day. In all, 66 % of those children
provided a urine and/or blood sample both at baseline and at
the end of the study. Mean age was 9·5 (SD 0·3) months and
25 % were stunted at enrolment (Table 1). There were no sig-
niﬁcant group-wise differences in baseline child characteristics
and maternal education. Maternal age and BMI were
signiﬁcantly higher in the LNS-Zn10 group compared with
mothers in the other two groups. Maternal and child
characteristics also did not differ between the children who
participated in the I study and the rest of the iLiNS-ZINC
participants, who were not included in the I assessment, except
for the prevalence of positive baseline RDT. Children in the
I study had a higher prevalence of positive baseline RDT than
those not included (68 v. 61 %; P= 0·041).
Over the course of the trial, caregivers of participants in the
IC reported very high adherence (98 (SD 2) %) to SQ-LNS. All the
children were breast-fed at 9 months, and 96·7 % of children
continued to be breast-fed at 18 months of age. In contrast, at
9 months of age, only 24·4 % consumed the minimum recom-
mended number of meals on the previous day and 15·5 % met
the minimum food group diversity recommended by the
WHO(20). Moreover, only 11·3 % consumed any kind of dairy
product and 22·3 % consumed any animal-source food on the
previous day. By 18 months of age, 60·0 % consumed the
minimum number of meals, but only 27·4 % met the minimum
food group diversity, 20·7 % consumed at least one dairy
product and 37·0 % consumed at least one source of animal
food during the previous 24 h.
The geometric mean UI concentration at baseline was 220
(95 % CI 192, 257) µg/l in children in the IC and 276 (95 % CI
192, 397) µg/l in children in the NIC (Table 2). Baseline UI
concentrations did not differ between the children in the IC and
NIC. For both cohorts combined, the mean UI was signiﬁcantly
higher at 18 months compared with 9 months of age
(P< 0·0001). Although the difference in UI between the IC and
NIC at 18 months of age was NS, there was a signiﬁcant inter-
action between intervention and age. In particular, UI was
signiﬁcantly higher at 18 months compared with 9 months of
age only in the IC (Pintervention× age= 0·035). Only 14·8 % of
participants had low UI concentration at baseline, which
declined to 4·0 % at 18 months of age. A large proportion of
children had high UI, with 18·8 and 32·3 % of children having
UI> 500 µg/l at 9 and 18 months, respectively, although there
are no speciﬁc cut-offs for excessive UI levels available for this
age group (Fig. 2). The baseline UI differed between the two
SQ-LNS intervention groups (P= 0·043), but this difference did
not persist at 18 months of age.
The geometric mean of the TSH concentration was 0·8 (95 %
CI 0·7, 0·9) mU/l both at baseline and at the end of the study.
Only one child had an elevated TSH concentration at baseline,
and all children had normal TSH concentrations at 18 months of
age. Similarly, most children had normal T4 concentrations at
9 and 18 months of age. The prevalence of hypothyroxinaemia
(low T4 concentration) was 3·4 % at baseline with no difference
between the groups. The prevalence remained low at
18 months of age, but there was a marginally signiﬁcant
difference between the IC and the NIC (1·6 v. 8·9 %; P= 0·052).
At baseline, the geometric mean of the Tg concentration was
signiﬁcantly higher in children in the NIC, 33·2 (95 % CI 28·8,
37·9) µg/l, compared with children in the IC, 27·5 (95 % CI 25·2,
29·9) µg/l (P= 0·005). However, Tg concentrations were not
signiﬁcantly different between the cohorts or the intervention
groups at 18 months of age after controlling for baseline values.
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There was also no signiﬁcant difference in the prevalence of
low or high Tg concentrations using the cut-offs for school-age
children(3), using standardised values and the upper and lower
2·5th percentiles of the adjusted baseline values of the whole
sample. None of these comparisons found a signiﬁcant differ-
ence in adjusted Tg by cohort. However, signiﬁcantly more
children (n 5; 6 %) in the NIC had adjusted Tg below the 2·5th
percentile (<10·6 µg/l) compared with children in the IC (n 1;
0·6 %; P= 0·006).
Salt samples (n 106) were successfully collected and analysed
from randomly selected households. The mean I content of
the salt samples was 37 ppm (ranging from 5 to 86 ppm). Only
5% of the salt samples had an I content<15 ppm and
37%< 30 ppm.
Discussion
I deﬁciency was not prevalent in the study participants at 9 and
18 months of age, and the majority of households had access to
adequately iodised salt. In all 63 % of the salt samples collected
at the household level had an I content of >30 ppm, the level
mandated in Burkina at retail distribution sites(14), and 95 % had
>15 ppm. These results are comparable with ﬁndings from the
most recent 2010 DHS, which found that 96 % of Burkinabe
households had access to salt-containing I> 15 ppm(28) and
conﬁrmed a signiﬁcant increase in programmatic coverage, as
only 34 % of salt samples were found to be iodised (>15 ppm)
during the 2003 DHS(15). The provision of 90 µg I/d in SQ-LNS
did not affect UI, TSH, T4 or Tg concentrations at the end of the
study, although children who received SQ-LNS had slightly
lower prevalence of low T4 and low Tg concentrations com-
pared with children from the NIC. Overall, the prevalence of
hypothyroxinaemia was relatively low in both cohorts.
Considering that the majority of children in both the IC and the
NIC had adequate I status based on all four I status indicators,
the salt iodisation programme seems to provide sufﬁcient I to
young children in the study area, either indirectly through the
consumption of breast milk or directly through the consumption
of salt-containing foods. To our knowledge, this was the ﬁrst
intervention trial investigating the impact of a home fortiﬁcation
product on young children’s I status.
TSH and T4 concentrations are homoeostatically controlled
(3),
and thus we did not expect that the provision of the additional
I would affect these biomarkers in already I-sufﬁcient popula-
tions. However, we expected that the provision of additional I
Table 1. Baseline characteristics of children and their mothers of the two intervention groups and the non-intervention cohort (NIC) participating in I status
assessments and compared with iLiNS-ZINC study participants not in the I status assessment
(Mean values and standard deviations; numbers and percentages)
LNS-Zn0 LNS-Zn10 NIC
P for the difference
In I subgroup
combined
Not in I
subgroup
Mean SD Mean SD Mean SD between group* Mean SD Mean SD P*
n (children with 9 and
18 months values)
92 88 104 284 2936
Age (months) 9·4 0·3 9·5 0·3 9·5 0·3 0·667 9·5 0·3 9·4 0·4 0·011
Male (n, %) 43 46·7 35 39·8 54 51·9 0·238 132 46·5 1488 50·7 0·127
Baseline child LAZ −1·29 0·98 −1·22 1·06 −1·22 1·11 0·857 −1·24 1·05 −1·20 1·10 0·659
Baseline child WLZ −1·06 1·19 −1·19 0·95 −1·05 1·13 0·634 −1·10 1·10 −0·98 1·05 0·085
Baseline Hb (g/l) 90 15 89 15 88 16 0·775 89 15 89 15 0·681
Anaemic (n, %) 87 94·6 83 94·3 95 91·3 0·723 265 93·3 2668 90·9 0·141
RDT positive (%) 65 70·6 62 70·4 66 63·5 0·583 193 68·0 1785 60·8 0·041
Maternal age (years) 25·9 5·9b 28·7 6·7a 26·1 7·0b 0·006 26·8 6·6 26·9 6·7 0·909
Maternal BMI (kg/m2) 20·4 1·8b 21·2 2·7a 20·6 2·2a,b 0·046 20·7 2·3 20·9 2·5 0·279
Maternal education 0·118 0·052
No formal or informal
education (n, %)
56 60·9 55 62·5 77 74·0 188 66·2 1731 59·6
Any informal education and/or
<1 year of formal education
(n, %)
29 31·5 23 26·1 18 17·3 70 24·6 857 29·5
At least 1 year of formal
education (n, %)
7 7·6 10 11·4 9 8·7 26 9·2 317 10·9
Baseline child dietary intake
Child still breast-fed (n, %) 91 100·0 88 100·0 104 100·0 1·000 283 100·0 2933 100·0 0·894
Consuming semi-solid or
solid food (n, %)†
69 92·0 58 85·3 64 86·5 0·443 191 88·0 2349 86·5 0·509
Minimum food group
diversity (n, %)‡
15 16·5 12 13·6 17 16·3 0·811 44 15·5 356 12·1 0·110
Animal-source food (n, %)§ 22 24·2 17 19·3 24 23·1 0·715 63 22·3 652 22·2 0·980
LAZ, length-for-age Z-score; LNS, lipid-based nutrient supplements; RDT, rapid diagnostic test; WLZ, weight-for-length Z-score.
a,b Values within a row with unlike superscript letters are significantly different (P<0·05).
* P values are from mixed model for continuous variables, Glimmix for binary variables and χ2 for polychotomous variables. All the analyses were adjusted for the random effect of
village.
† Child consumed at least one semi-solid or solid food item during the previous 24 h.
‡ Child received food from four or more food groups during the previous 24 h.
§ Child consumed at least one animal-source food during the previous 24 h.
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Table 2. Urinary iodine (UI), thyroid-stimulating hormone (TSH), total thyroxine (T4) and thyroglobulin (Tg) concentrations in children at 9 and 18 months of age participating in the iLiNS-ZINC trial
(Geometric means and 95% confidence intervals; numbers and percentages)
IC* NIC* LNS-Zn0* LNS-Zn10*
Mean 95% CI Mean 95% CI P between cohorts† Mean 95% CI Mean 95% CI P between two intervention groups†
UI
n at 9 and at 18 months 143 80 76 67
UI at 9 months (µg/l) 222 192, 257 276 192, 397 0·103 254 208, 311 191 157, 232 0·043
UI at 18 months (µg/l) 356 314, 404 310 227, 425 0·380 354 296, 424 358 298, 432 0·744
Low UI at 9 months (<100 µg/l; n, %) 25 17·5 8 10·0 0·145 10 13·2 15 22·4 0·161
High UI at 9 months (>500 µg/l, n, %) 27 18·9 15 18·8 0·906 16 21·1 11 16·4 0·456
Low UI at 18 months (<100 µg/l, n, %) 5 3·5 4 5·0 0·993 3 3·9 2 3·0 0·593
High UI at 18 months (>500 µg/l, n, %) 50 35·0 22 27·5 0·271 27 35·5 23 34·3 0·896
TSH
n at 9 and 18 months 123 56 65 58
TSH at 9 months (mU/l) 0·8 0·7, 0·9 0·8 0·7, 1·0 0·394 0·8 0·7, 0·9 0·7 0·6, 0·9 0·263
TSH at 18 months (mU/l, n, %) 0·8 0·7, 0·9 0·8 0·7, 0·9 0·837 0·8 0·7, 1·0 0·7 0·7, 0·8 0·402
High TSH at 9 months (>3·7mU/l, n, %) 1 0·8 0 0 0·991 0 0 1 1·7 0·980
High TSH at 18 months (>3·7mU/l) 0 0 1·000 0 0 1·000
Total T4
n at 9 and at 18 months 123 56 65 58
T4 at 9 months (nmol/l) 127 119, 136 135 125, 146 0·292 129 119, 140 126 112, 139 0·669
T4 at 18 months (nmol/l) 117 113, 122 119 110, 128 0·806 117 111, 122 118 110, 125 0·472
Low T4 at 9 months (<65 nmol/l, n, %) 4 3·2 2 3·6 0·680 3 4·6 1 1·7 0·377
Low T4 at 18 months (<65 nmol/l, n, %) 2 1·6 5 8·9 0·052 1 1·5 1 1·7 0·911
Tg
n at 9 and 18 months 154 83 81 73
Tg at 9 months (µg/l) 27·5 25·2, 29·9 33·2 28·8, 37·9 0·005 26·8 24·0, 29·7 28·4 24·7, 32·3 0·464
Tg at 18 months (µg/l) 25·9 23·7, 28·3 26·1 23·3, 29·0 0·082 24·1 21·5, 26·8 28·0 24·5, 31·9 0·050
Low Tg at 9 months (Tg<4 µg/l) 0 0 1·000 0 0 1·000
High Tg at 9 months (Tg >40 µg/l, n, %) 28 18·2 29 34·9 0·002 12 14·8 16 21·9 0·308
Low Tg at 18 months (Tg<4 µg/l, n, %) 0 2 2·4 0·979 0 0 0·999
High Tg at 18 months (Tg> 40 µg/l, n, %) 29 18·8 17 20·5 0·323 14 17·3 15 20·5 0·883
IC, intervention cohort; LNS, lipid-based nutrient supplements; NIC, non-intervention cohort; SQ-LNS, small-quantity lipid-based nutrient supplements.
* Communities were cluster randomised to IC and NIC. Within the IC, children were randomly assigned to receive 20 g LNS/d containing 90 µg I with 0mg Zn (LNS-Zn0) or 10 mg Zn (LNS-Zn10) from 9–18 months, and NIC children
received no SQ-LNS. All the children received iodised salt through the national salt iodization programme.
† Adjusting for cluster randomisation (village) and age during the visit and for baseline value additionally for analysis at 18 months of age.
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via SQ-LNS would have increased UI concentration. Possible
explanations for the lack of the observed increase in UI are (1)
less than reported adherence to SQ-LNS, (2) instability of I in
SQ-LNS and/or (3) storage of excess I in the thyroid gland.
The present study included a variety of methods to assess
adherence(21). Although caregivers’ reports of adherence
(97 (SD 6) %) and disappearance rate of returned empty
packages (98 (SD 4) %) implied very high adherence in the
present study, 12 h home observations during home visits found
that only 59 % of the children were offered SQ-LNS during the
hours of observation(21). Moreover, during interviews assessing
knowledge, attitude and practices related to SQ-LNS at
15 months of age, half of the caregivers reported sharing of
SQ-LNS during the previous week, mostly with other siblings.
Thus, it is likely that the additional I intake from SQ-LNS was
<90 µg/l, which would likely also be the case in any programme
setting. Although adequate amounts of I in SQ-LNS were
conﬁrmed at the time of production, and products were tested
for long-term stability, it cannot be ruled out that there was
some loss of I from SQ-LNS over time due to oxidation. The
I content of the thyroid gland is 0·1 mg at birth and increases to
8–15mg by adulthood; therefore, it is also possible that some of
the additionally provided I was taken up by the thyroid gland
and stored rather than excreted.
Dietary I intake was not assessed in our study population.
However, based on non-quantitative food frequency ques-
tionnaires, children’s diets were primarily based on cereal, with
poor reported dietary diversity and intake of animal-source
foods, including dairy, at 9 and 18 months of age(20). Based on
this presumed inadequate dietary intake, it can be assumed that
the I intake from foods containing iodised salt was limited,
particularly at 9 months of age. In contrast, considering that all
the children were breast-fed at 9 months and almost all children
continued to be breast-fed at 18 months of age, it is likely that
most children beneﬁtted from the salt iodisation programme
indirectly via breast milk. The I content of breast milk varies
widely and depends on the maternal I status(29).
The tolerable upper intake level (UL), the highest average
daily I intake that is likely not to pose adverse health risks, is set
at 200 µg I/d for children aged between 1and 3 years(6,30).
Assuming a breast milk consumption of 620 and 550 g/d at
9 and 18 months, respectively(31), and a median breast milk I
content of 146 µg/l as found in a study in the USA among
women with adequate I intake(32), the frequently breast-fed
iLiNS-ZINC study participants consumed approximately
80–90 µg I/d through breast milk. Little is known about salt
intake among young African children, but assuming a salt intake
of 2 g/d(33) and considering the median I content of salt of
37 ppm, I intake from salt would be approximately 74 µg/d.
Thus, based on these estimates, children in this setting may
already consume more than the UL even without considering
the I provided in SQ-LNS. At present, no cut-off of UI has been
established to identify young children with excessive I intakes
and the normal range for Tg has not been determined for early
childhood(3,26). All children in the study population had normal
TSH concentrations and most had T4 concentrations within the
normal range, implying normal thyroid function. This leads us
to the conclusion that, although providing 90 µg additional I/d
in SQ-LNS may have been more than necessary, it does not
seem to have adversely affected thyroid metabolism at
18 months of age.
This is the ﬁrst randomised clinical trial assessing the impact
of providing Zn on I status. The addition of 10 mg Zn to a daily
ration of SQ-LNS did not have an impact on any of the
measured indicators of I status and thyroid metabolism. To date,
the evidence of interactions between I and Zn metabolism is
inconclusive and is mostly based on cross-sectional studies in
humans(16). One Zn-depletion study in six young men found
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Fig. 2. Distribution of urinary iodine (UI) concentration at 9 and 18 months of age.
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that serum TSH, total T4 and free T4 concentrations tended to
decrease during the period of low Zn intake (5·5 mg/d for 54 d),
but only free T4 was signiﬁcantly reduced
(34). It is possible that
Zn deﬁciency was not severe enough in the study population
to have affected thyroid metabolism. Zn deﬁciency was
common and 35 and 54 % of children at 9 and 18 months,
respectively, had low plasma Zn concentration (<650 µg/l)(11).
However, the intervention also had no effect on plasma Zn
concentration, possibly indicating inadequate adherence to the
study supplements or poor Zn absorption.
Strengths of this study include the high participation rates and
continuous training and rigorous supervision of ﬁeld staff. In
addition, I status was assessed using a variety of recommended
biochemical indicators in urine and blood, the salt iodisation
programme was assessed by titration of salt samples collected
from participating families and multiple strategies were used
to assess adherence to SQ-LNS(21). Thus, the present study
provided a broad overview of I and thyroid status, as well as
potential dietary sources of I. The target sample size was
calculated based on an effect size of 0·6 and a three-group
comparison (with a signiﬁcance level of P< 0·05 and
power>0·80). However, considering the study objectives, we
decided that two-group comparisons (IC v. NIC; LNS-Zn0 v.
LNS-Zn10) would be more appropriate. Post hoc power calcu-
lations show that we were powered to detect an effect size of
0·54 and 0·55 for Tg and UI concentrations, respectively, and
0·67 for TSH and T4 concentrations for the comparison between
the IC and the NIC. Thus, our sample was less adequate for
comparing TSH and T4 concentrations than originally planned.
However, as the mean concentrations of these indicators were
so similar, it is unlikely that a larger sample size would have
inﬂuenced our conclusions.
In conclusion, in settings with high coverage of universal salt
iodisation and continued breast-feeding, a reduction in the I
content added to home fortiﬁcation products such as SQ-LNS
should be considered. Before including I in home fortiﬁcation
products in countries with established salt iodisation pro-
grammes, salt samples should be tested at the household level
for adequate I content, and ideally I status of the target popu-
lation should be assessed. However, further assessments are
needed in other countries, particularly in countries where the
universal salt iodisation programme is less well established.
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